Literature DB >> 34648126

Impaired mitochondrial functions and energy metabolism in MPTP-induced Parkinson's disease: comparison of mice strains and dose regimens.

Anjana Pathania1, Priyanka Garg1, Rajat Sandhir2.   

Abstract

Heterogenous diseases such as Parkinson's disease (PD) needs an efficient animal model to enhance understanding of the underlying mechanisms and to develop therapeutics. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin, has been widely used to replicate the pathophysiology of PD in rodents, however, the knowledge about its effects on energy metabolism is limited. Moreover, susceptibility to different dose regimens of MPTP also varies among mice strains. Thus, the present study compares the effect of acute and sub-acute MPTP administration on mitochondrial functions in C57BL/6 and BALB/c mice. In addition, activity of enzymes involved in energy metabolism was also studied along with behavioural alterations. The findings show that acute dose of MPTP in C57BL/6 mice had more profound effect on the activity of electron transport chain complexes. Further, the activity of MAO-B was increased following acute and sub-acute MPTP administration in C57BL/6 mice. However, no significant change was observed in BALB/c mice. Acute MPTP treatment resulted in decreased mitochondrial membrane potential along with increased swelling of mitochondria in C57BL/6 mice. In addition, perturbations were observed in hexokinase, the rate limiting enzyme of glycolysis and pyruvate dehydrogenase, the enzymes that connects glycolysis and TCA cycle. The activity of TCA cycle enzymes; citrate synthase, aconitase, isocitrate dehydrogenase and fumarase were also altered following MPTP intoxication. Furthermore, acute MPTP administration led to drastic reduction in dopamine levels in striatum of C57BL/6 as compared to BALB/c mice. Behavioral tests such as open field, narrow beam walk and footprint analysis revealed severe impairment in locomotor activity in C57BL/6 mice. These results clearly demonstrate that C57BL/6 strain is more vulnerable to MPTP-induced mitochondrial dysfunctions, perturbations in energy metabolism and motor defects as compared to BALB/c strain. Thus, the findings suggest that the dose and strain of mice need to be considered for pre-clinical studies using MPTP-induced model of Parkinson's disease.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BALB/c; Behaviour; C57BL/6; Cytochrome c oxidase; Dopamine; F1–F0 ATPase Synthase; MPTP; Mitochondria; NADH Dehydrogenase; Neurotransmitter; Parkinson’s disease; Succinate Dehydrogenase

Mesh:

Substances:

Year:  2021        PMID: 34648126     DOI: 10.1007/s11011-021-00840-2

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  43 in total

1.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death.

Authors:  Frédéric Darios; Olga Corti; Christoph B Lücking; Cornelia Hampe; Marie-Paule Muriel; Nacer Abbas; Wen-Jie Gu; Etienne C Hirsch; Thomas Rooney; Merle Ruberg; Alexis Brice
Journal:  Hum Mol Genet       Date:  2003-03-01       Impact factor: 6.150

2.  Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration.

Authors:  G P Davey; S Peuchen; J B Clark
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

Review 3.  Invited Article: Nervous system pathology in sporadic Parkinson disease.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Neurology       Date:  2008-05-13       Impact factor: 9.910

Review 4.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

5.  Cortical glucose metabolism in Parkinson's disease without dementia.

Authors:  J L Eberling; B C Richardson; B R Reed; N Wolfe; W J Jagust
Journal:  Neurobiol Aging       Date:  1994 May-Jun       Impact factor: 4.673

6.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy.

Authors:  O Blin; C Desnuelle; O Rascol; M Borg; H Peyro Saint Paul; J P Azulay; F Billé; D Figarella; F Coulom; J F Pellissier
Journal:  J Neurol Sci       Date:  1994-08       Impact factor: 3.181

7.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection.

Authors:  Shiek Ssj Ahmed; Winkins Santosh; Suresh Kumar; Hema T Thanka Christlet
Journal:  J Biomed Sci       Date:  2009-07-13       Impact factor: 8.410

Review 8.  Animal models of neurological deficits: how relevant is the rat?

Authors:  M Angela Cenci; Ian Q Whishaw; Timothy Schallert
Journal:  Nat Rev Neurosci       Date:  2002-07       Impact factor: 34.870

9.  Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.

Authors:  Giovanni Cirillo; Nicola Maggio; Maria Rosaria Bianco; Cecilia Vollono; Stefania Sellitti; Michele Papa
Journal:  Neurochem Int       Date:  2009-09-30       Impact factor: 3.921

10.  Column chromatography analysis of brain tissue: an advanced laboratory exercise for neuroscience majors.

Authors:  William H Church
Journal:  J Undergrad Neurosci Educ       Date:  2005-06-15
View more
  3 in total

Review 1.  Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson's Disease: a Systematic Review.

Authors:  Michele Goulart Dos Santos; Lucia Emanueli Schimith; Corinne André-Miral; Ana Luiza Muccillo-Baisch; Bruno Dutra Arbo; Mariana Appel Hort
Journal:  Neurotox Res       Date:  2022-01-11       Impact factor: 3.911

Review 2.  Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson's disease.

Authors:  Richard M Kostrzewa
Journal:  J Neural Transm (Vienna)       Date:  2022-03-12       Impact factor: 3.850

3.  Calcium carbonate supplementation causes motor dysfunction.

Authors:  Ami Sugiura; Misa Kitamura; Yasushi Hasegawa
Journal:  Exp Anim       Date:  2022-05-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.